Influence of Initial Therapy on Outcome of Peptic Ulcer

References

• Hansky J, Korman MG. Long-term cimetidine in duodenal ulcer. Dig Dis Sci 1979; 24: 465–7
   PubMed Web of Science ®Google Scholar
• Bardham K D, Hinchcliffe R FC, Rose K, et al. Six years of continuous cimetidine treatment in peptic ulcer disease, 'efficacy and safety'. Aliment Pharmacol Therap 1988; 2: 394–405
   Google Scholar
• Penston J G, Wormsley KG. Efficacy and safety of long-term maintenance therapy of duodenal ulcers. Scand J Gastroenterol 1989; 24: 1145–52
   PubMed Web of Science ®Google Scholar
• Pounder RE. Maintenance treatment: who should be treated and for how long?. Maintenance treatment, a strategy for the management of peptic ulcer disease. The Medicine Group (UK) Ltd, Oxford 1988; 14–5
   Google Scholar
• Freston J. H2 receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs and patient selection. Am J Gastroenterol 1987; 82: 1242–9
   PubMed Web of Science ®Google Scholar
• Glise H, Martinson J, Solhaug J H, Carling L, Unge P, Engström G, et al. Two and four weeks' treatment for duodenal ulcer. Symptom relief and clinical remission comparing omeprazole and ranitidine. Scand J Gastroenterol 1991; 26: 137–45
   PubMed Web of Science ®Google Scholar
• Bardhan K D, Naesdal J, Bianchi Porro G, Petrillo M, Lazzaroni M, Hinchliffe R F, et al. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists; a controlled clinical trial. Gut 1991; 32: 435–8
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Andersen B N, Laursen L S, Hansen J, Havelund T, Eriksen J, et al. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Gastroenterology 1991; 100: 663–9
   PubMed Web of Science ®Google Scholar
• Pounder R E, Festen H, Korman MG. The long-term management of duodenal ulceration using an H2 antagonist: symptomatic self-care compared with maintenance therapy. Aliment Pharmacol Ther 1992; 6: 315–25
   PubMed Web of Science ®Google Scholar
• Korman M G, Hansky J, Eaves E R, Schmidt GT. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983; 85: 871–4
   PubMed Web of Science ®Google Scholar
• Coggon D, Lambert P, Langman M JS. 20 years of hospital admissions for peptic ulcer in England and Wales. Lancet 1981; 1: 1302–4
   PubMed Web of Science ®Google Scholar
• McLean A J, Harrison P M, Ioannides-Demos L, Byrne A J, McCarthy P, Dudley FJ. The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term clinical outcome. Aust NZJ Med 1985; 15: 367–74
   PubMedGoogle Scholar
• Chiverton S G, Hunt RH. Initial therapy and relapse of duodenal ulcer: possible acid secretory mechanisms. Gastroenterology 1989; 6: 632–9, Suppl
   Google Scholar
• Marks I N, Wright J P, Lucke W, Girdwood AH. Relapse rates after initial ulcer healing with sucralfate and cimetidine. Scand J Gastroenerol 1982; 17: 429–32
   PubMed Web of Science ®Google Scholar
• Domschke S, Domschke W. Longer relapse-free period after sucralfate than after H2 treatment of duodenal and gastric ulcers. Am J Med 1991; 1: 74S–84S, Suppl 2A
   Google Scholar
• Tovey F I, Husband E M, Yiu Y C, Baker L, McPhail G, Lewin M R, et al. Comparison of relapse rates and of mucosal abnormalities after healing of duodenal ulceration and after one year's maintenance with cimetidine or sucralfate. Gut 1989; 30: 586–93
   PubMed Web of Science ®Google Scholar
• Fullarton G M, McLauchlan G, MacDonald A, Crean G P, McColl KE. Rebound nocturnal hypersecretion after four weeks' treatment with an H2 receptor antagonist. Gut 1989; 30: 449–54
   PubMed Web of Science ®Google Scholar
• Jones D B, Howden C W, Burget D W, Silletti C, Hunt RH. Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist. Gut 1988; 29: 890–3
   PubMed Web of Science ®Google Scholar
• Nwokolo C U, Smith J TL, Gavey C J, Sawyer A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Therap 1990; 4: 29–45, Suppl 1
   PubMed Web of Science ®Google Scholar
• Szabo S, Vattay P, Scarbrough E, Folkman J. Role of vascular factors, including angiogenesis, in the mechanisms of action of sucralfate. Am J Med 1991; 91: 158S–60S
   PubMed Web of Science ®Google Scholar
• Wyatt J I, Rathbone B J, Dixon M F, Heatley RV. Campylobacter pyloridis and acid-induced gastric metaplasia in the pathogenesis of duodenitits. J Clin Pathol 1987; 40: 841–8
   PubMed Web of Science ®Google Scholar
• Levi S, Beardshall K, Haddad G, Playford R, Ghosh P, Calam J. Campylobacter pylori and duodenal ulcers. The gastrin link. Lancet 1989; 1: 1167–8
   PubMed Web of Science ®Google Scholar
• Rauws E AJ, Tytgat G NJ. Eradication of Helicobacter pylori cures duodenal ulcer. Lancet 1990; 1: 1233–5
   Web of Science ®Google Scholar
• Unge P, Gad A, Eriksson K, et al. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol 1993; 5: 325–31
   Web of Science ®Google Scholar